The strong H1 beat and maintained guidance at the upper end are clear positives, but the ATM facility creates potential dilution. Traders should watch for the prospectus supplement filing to gauge the pace and size of any ATM sales, which could cap near-term upside. The PDUFA date for Pixclara on September 11, 2026, is a key catalyst.
Drugs in focus
TLX drug pipeline →TLX591-Tx
● Neutral Named in this press release- Impact
- Phase
- Phase 3
- Time to market
- Likely 2028+ (Phase 3 Part 2 enrollment underway, followed by event-driven rPFS readout, then regulatory filing)
- Next catalyst
- None dated
What to watchWatch for enrollment completion updates on ProstACT Global Part 2 and any interim rPFS data. The stock is heavily influenced by Illuccix/Gozellix revenue execution, so TLX591-Tx is a pipeline upside option, not the core thesis today. Near-term catalysts center on Telix's imaging franchise (Pixclara PDUFA) rather than this therapeutic.
- ● Zircaix 4/10 Phase 3 (ZIRCON) completed; BLA under FDA review Named in filing
- ▲ Gozellix 3/10 Approved (FDA, March 21, 2025 — NDA 219592, 505(b)(2)) Named in filing
- ● TLX101-Tx 3/10 Phase 3 (pivotal, just initiated); Phase 1 safety stage complete Named in filing
- ◆ ITM-11 4/10 Phase 3 (completed)
- All TLX drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 20 $12.42entry
- T+1 · 3mo ago −8.78%α −9.19% · $11.33
- T+5 · 3mo ago −8.41%α −9.53% · $11.38
- T+20 · 2mo ago +0.68%α +0.68% · $12.51
- T+60 · 4d ago −24.64%α −23.80% · $9.36
Price Chart
How similar events traded
Executive Summary
Telix Pharmaceuticals reported H1 2026 revenue of $477M, up 22% YoY, and a net profit of $38M vs a loss of $2M in H1 2025, driven by strong commercial performance and a $40M non-refundable payment from Regeneron. The company reaffirmed FY 2026 revenue guidance at the upper end of $950M-$970M and expects total revenue and other income to exceed $1B, while also establishing an ATM facility for potential equity issuance. The strong beat on profitability and maintained guidance are positive, but the ATM facility introduces dilution overhang, tempering the overall bullish signal.
Key Financial Metrics
Key Facts
- H1 2026 revenue of $477M, up 22% YoY from $390M
- Net profit of $38M vs loss of $2M in H1 2025
- Adjusted EBITDA of $52M, up 146% YoY from $21M
- Precision Medicine segment revenue up 27% YoY with gross margin of 65%
- FY 2026 revenue guidance reaffirmed at upper end of $950M-$970M, total revenue and other income expected to exceed $1B
- Established an ATM facility to sell up to undisclosed amount of ADSs at market prices
- Cash balance of $252M as of June 30, 2026
- Entered strategic collaboration with Regeneron, receiving $40M initial payment
Financial Impact
Revenue of $477M vs consensus $311.6M (beat by ~53%), net profit of $38M vs consensus EPS of -$0.01 (strong beat). FY guidance of $950M-$970M revenue implies H2 revenue of $473M-$493M.
Risk Factors
- ATM facility could lead to dilution if shares are sold at current market prices
- R&D spending of $124M in H1 (vs $82M in H1 2025) may pressure near-term profitability if revenue growth slows
- BLA resubmission for Zircaix (TLX250-Px) remains pending with FDA
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3348062 |
Track record
27 reports on TLX
10 of 20 bullish or bearish reports moved the stock their way by T+1. Best: +29.26% at T+20 after the Jun 1, 2026 report. 18 of 20 went positive at some point.
Filters
- Oct 29, 202618d ago 6-K Neutral 5/10 Entry $9.10 to $9.05 Now $8.92 −1.98% ▼ −0.55% −0.07% vs SPY
- Oct 20, 202627d ago 6-K Neutral 4/10 No price data
- Oct 20, 202627d ago Press Release Bullish 6/10 Entry $10.03 to $9.54 Now $8.92 −11.07% ▼ −4.89% −3.70% vs SPY
- Sep 29, 20266w ago 6-K Bullish 6/10 Entry $10.97 to $10.72 Now $8.92 −18.69% ▼ −2.28% −2.46% vs SPY
- Sep 21, 20268w ago 6-K Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
- Sep 20, 20268w ago Press Release Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
- Sep 14, 20269w ago 6-K Bullish 8/10 Entry $12.83 to $11.83 Now $8.92 −30.48% ▼ −7.79% −7.35% vs SPY
- Sep 14, 20269w ago Press Release Bullish 8/10 Entry $11.78 to $12.83 Now $8.92 −24.28% ▲ +8.91% +9.37% vs SPY
- Sep 1, 202610w ago 6-K Bullish 7/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
- Sep 1, 202610w ago Press Release Bullish 6/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers